Healthcare diagnostics company Labcorp Holdings (NYSE: LH) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $3.53 billion. Its non-GAAP profit of $4.35 per share was 4.5% above analysts’ consensus estimates.

Is now the time to buy LH? Find out in our full research report (it’s free).

StockStory’s Take

Labcorp’s second quarter was marked by broad-based revenue growth and improved profitability, prompting a strong positive market reaction. Management attributed this momentum to robust organic growth in its Diagnostics Laboratory segment, supported by recent acquisitions and expanding partnerships with hospitals and regional labs. CEO Adam Schechter noted that specialty testing areas—such as oncology, women’s health, and neurology—continue to outpace the broader market, helping drive both volume and an improved mix of higher-value tests. The company also highlighted its progress integrating Invitae and the benefits of new hospital laboratory agreements, which have contributed to increased market share and operational leverage.

Looking ahead, Labcorp’s raised full-year guidance is supported by expectations of sustained demand in specialty diagnostics and continued execution of acquisition-driven growth. Management emphasized the durability of volume trends, with Schechter citing factors like an aging population and increased disease prevalence. The company is also preparing for potential regulatory changes, including possible reimbursement reductions under PAMA, and plans to offset headwinds through operational efficiencies. CFO Julia Wang stated, “We expect strong utilization to continue into the second half of the year as part of our guide,” underlining confidence in both the core business and the recent Invitae integration.

Key Insights from Management’s Remarks

Management identified several drivers behind the quarter’s results, focusing on specialty testing, partnerships with hospitals, and ongoing cost efficiencies.

• Specialty testing momentum: Growth in oncology, neurology, autoimmune, and women’s health diagnostics remains strong, with these areas growing three to four times faster than routine testing. Schechter explained that specialty patients often require broader panels of tests, which lifts both volume and average revenue per test.
• Hospital partnerships and acquisitions: Recent deals, such as the agreement to acquire assets from Community Health Systems and ongoing integration of other hospital lab operations, have expanded Labcorp’s geographic reach and improved margins. Management stressed that these outreach businesses typically contribute higher profitability and support inorganic growth targets.
• Biopharma Laboratory Services recovery: The biopharma segment saw an uptick in both central lab and early development activity, with a strong book-to-bill ratio (1.18 for the quarter) indicating healthy demand pipelines. Management cautioned that early development growth benefited from easier year-ago comparisons but expects steady mid-single digit growth for the full year.
• Operational efficiency initiatives: The LaunchPad cost program and technology investments, including digital and AI solutions, helped offset rising personnel costs and contributed to enterprise margin expansion. Wang noted that margin improvements were achieved despite headwinds from Invitae’s integration.
• Regulatory and reimbursement landscape: Management discussed ongoing legislative and regulatory risks, particularly the potential impact of changes to PAMA (Protecting Access to Medicare Act), noting a possible $100 million annual headwind. Labcorp has contingency plans to mitigate these effects through additional cost savings and process improvements.

Drivers of Future Performance

Labcorp’s outlook for the remainder of the year is shaped by sustained demand in specialty diagnostics, continued inorganic growth, and a focus on cost discipline amid regulatory uncertainties.

• Specialty testing and mix shift: Management expects ongoing strength in specialty areas to drive higher test volumes and improve revenue mix. Growth in oncology, women’s health, and neurology testing is projected to remain above market rates, benefiting from new product launches and expanded scientific partnerships.
• Acquisitions and hospital deals: Recently announced and pending acquisitions, including Community Health Systems’ outreach assets and select oncology testing businesses, are expected to contribute to both revenue growth and margin improvement. Schechter indicated these deals are structured to be accretive within the first year and help Labcorp gain market share in key regions.
• Cost management and regulatory risk: Labcorp is preparing for potential reimbursement headwinds, especially from possible PAMA cuts in 2026, by accelerating its LaunchPad efficiency initiatives and leveraging technology to contain costs. Management believes that these actions, combined with ongoing volume growth, should help sustain margin expansion even if some regulatory risks materialize.

Catalysts in Upcoming Quarters

Looking forward, our team will be monitoring (1) the pace of integration and early performance of recent hospital and outreach lab acquisitions, (2) trends in specialty test volume and average revenue per accession, and (3) Labcorp’s ability to offset regulatory headwinds—particularly any developments related to PAMA reimbursement changes. Continued progress on operational cost initiatives and the rollout of new specialty diagnostics will also be important signposts.

Labcorp currently trades at $270, up from $250.67 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s April 2024 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.